Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic renal anemia~* Hemoglobin concentration between 10.5 gram per deciliter (g/dL) and 12.5 g/dL~* Adequate iron status (serum ferritin greater than \[\>\] 100 nanogram per milliliter and Transferrin Saturation \>20 percent \[%\] or hypochromic red cells less than \[\<\] 10%)~* Continuous subcutaneous maintenance darbepoetin alfa therapy with same dosing interval during previous 2 months~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months~* Poorly controlled hypertension requiring hospitalization or interruption of darbepoetin alfa treatment in previous 6 months~* Acute or chronic bleeding~* Active malignant disease (except non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C.E.R.A. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).